Spero Therapeutics (SPRO) to Release Quarterly Earnings on Wednesday

Spero Therapeutics (NASDAQ:SPRO) is projected to issue its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $43.3390 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Thursday, March 26th. The company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.73. The firm had revenue of $41.30 million during the quarter, compared to the consensus estimate of $26.00 million. Spero Therapeutics had a return on equity of 22.53% and a net margin of 12.83%.

Spero Therapeutics Price Performance

SPRO opened at $2.42 on Wednesday. The company has a market capitalization of $140.12 million, a price-to-earnings ratio of 20.17 and a beta of 1.43. Spero Therapeutics has a 1-year low of $0.57 and a 1-year high of $3.22. The business has a 50 day moving average price of $2.50 and a two-hundred day moving average price of $2.41.

Analysts Set New Price Targets

SPRO has been the subject of a number of research analyst reports. Wall Street Zen upgraded Spero Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Sunday, March 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

Insider Activity at Spero Therapeutics

In other news, insider Esther Rajavelu sold 87,917 shares of the stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.36, for a total transaction of $207,484.12. Following the completion of the sale, the insider owned 1,012,091 shares in the company, valued at approximately $2,388,534.76. This represents a 7.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Spero Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. GSK plc acquired a new stake in shares of Spero Therapeutics during the 4th quarter valued at $21,414,000. Vanguard Group Inc. lifted its position in shares of Spero Therapeutics by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock valued at $3,741,000 after acquiring an additional 39,474 shares during the last quarter. State Street Corp lifted its position in shares of Spero Therapeutics by 10.1% during the 4th quarter. State Street Corp now owns 210,151 shares of the company’s stock valued at $490,000 after acquiring an additional 19,200 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Spero Therapeutics in the third quarter valued at $283,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Spero Therapeutics in the fourth quarter valued at $306,000. Institutional investors and hedge funds own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug?resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram?negative pathogens.